hBM-MSC-Derived EVs Improved Pulmonary Vascular Remodeling and Right Ventricle Function in a Mouse Pulmonary Hypertension Model.
文献摘要
Pulmonary hypertension (PH) is characterized by elevated mean pulmonary arterial pressure (mPAP), pulmonary vascular remodeling, and right ventricle (RV) hypertrophy and failure. PH is a rare disease, with significant morbidity and limited therapeutic options. Human Mesenchymal Stem-cell derived (hMSC) extracellular vesicles (EVs) have shown potential in improving pulmonary artery flow and RV function. The aim of this study was to evaluate the therapeutic effects of hMSC-EVs in a mouse model of monocrotaline (MCT)-induced PH. MCT + EVs animals compared to MCT + vehicle alone demonstrated improvement in RV function with an increase in Tricuspid Annular Plane Systolic Excursion by 37.1 ± 2.6% ( p = 0.0011) and reduction in RV hypertrophy by 18.6 ± 7.6% ( p = 0.0218) using Fulton's index. Pulmonary artery flow, evaluated by echocardiography of pulmonary artery acceleration time, was improved with EV treatment by 18.5 ± 1.3% ( p = 0.0419). Histological studies demonstrated a corresponding reduction in pulmonary arteriolar muscularization by 41.2 ± 18.5% ( p = 0.0004). Western blot analysis of MCT + EVs versus MCT + vehicle demonstrated modulations in proteins related to metabolism and cellular energetics in lungs and to calcium sequestration in RV. Proteomic analysis of circulating EVs from MCT + EVs versus MCT + vehicle groups revealed upregulation of proteasome and autophagy pathways in MCT + vehicle, which were attenuated by hMSC-EV. These results support a promising role for EVs in improving pulmonary vascular remodeling and RV function in PH by modulating signaling pathways involved in proteasome, autophagy, cellular energetic and metabolism.